Thrivent Financial for Lutherans Has $4.05 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Thrivent Financial for Lutherans lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 21.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 224,511 shares of the company’s stock after acquiring an additional 40,218 shares during the period. Thrivent Financial for Lutherans’ holdings in Teva Pharmaceutical Industries were worth $4,046,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of TEVA. Vanguard Group Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock worth $11,648,000 after purchasing an additional 28,071 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $166,000. UniSuper Management Pty Ltd lifted its position in shares of Teva Pharmaceutical Industries by 109.2% in the 1st quarter. UniSuper Management Pty Ltd now owns 15,900 shares of the company’s stock worth $224,000 after acquiring an additional 8,300 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. Finally, PEAK6 Investments LLC grew its holdings in shares of Teva Pharmaceutical Industries by 105.7% during the 1st quarter. PEAK6 Investments LLC now owns 54,868 shares of the company’s stock worth $774,000 after purchasing an additional 1,025,261 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.67.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $17.12 on Monday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The stock has a market capitalization of $19.40 billion, a P/E ratio of -20.14, a P/E/G ratio of 1.33 and a beta of 0.87. The business has a 50-day moving average price of $17.67 and a two-hundred day moving average price of $17.34.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.